Targeting the SH2 domain of Stat3 with phosphopeptide mimetic prodrugs leads to tumor growth inhibition and down-regulation of phosphoTyr705 Stat3 and angiogenic pathways

被引：0
|
作者：
McMurray, J. [1 ]
Klostergaard, J. [1 ]
Auzenne, E. J. [1 ]
Liao, W. S. L. [1 ]
Lu, Z. [1 ]
Mandal, P. K. [1 ]
Ramesh, R. [1 ]
Shanker, M. [1 ]
Scott, A. W. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72129-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [21] STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters
    Jo, Dong Hyun
    Kim, Jin Hyoung
    Cho, Chang Sik
    Cho, Young-Lai
    Jun, Hyoung Oh
    Yu, Young Suk
    Min, Jeong-Ki
    Kim, Jeong Hun
    ONCOTARGET, 2014, 5 (22) : 11513 - 11525
  • [22] Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening
    Hao, Wenshan
    Hu, Yongbo
    Niu, Chuansheng
    Huang, Xinyi
    Chang, Chao-Pei Betty
    Gibbons, James
    Xu, Jun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (18) : 4988 - 4992
  • [23] Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth
    Xia Li
    Hongguang Ma
    Lin Li
    Yifan Chen
    Xiao Sun
    Zizheng Dong
    Jing-Yuan Liu
    Weiming Zhu
    Jian-Ting Zhang
    Oncogene, 2018, 37 : 2469 - 2480
  • [24] Inhibition of Stat3 recruitment and activation by YXXQ-containing phospho-dodecapeptides: Contribution of Stat3 SH2 residues that interact with the +3 Q residue.
    Shao, H
    Tweardy, DJ
    BLOOD, 2001, 98 (11) : 573A - 573A
  • [25] Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth
    Li, Xia
    Ma, Hongguang
    Li, Lin
    Chen, Yifan
    Sun, Xiao
    Dong, Zizheng
    Liu, Jing-Yuan
    Zhu, Weiming
    Zhang, Jian-Ting
    ONCOGENE, 2018, 37 (18) : 2469 - 2480
  • [26] In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity
    Szelag, Malgorzata
    Sikorski, Krzysztof
    Czerwoniec, Anna
    Szatkowska, Katarzyna
    Wesoly, Joanna
    Bluyssen, Hans A. R.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 720 (1-3) : 38 - 48
  • [27] SH2-domain targeted Stat3 prodrugs inhibit target phosphorylation and proliferation of lung tumor cell lines
    Ramesh, Rajagopal
    Shanker, Manish
    Scott, Aileen
    Mandal, Pijus
    Liao, Warren
    Elizondo, Stephanie
    Ren, Zhiyong
    Chen, Xiaomin
    McMurray, John
    CANCER RESEARCH, 2009, 69
  • [28] Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations
    Fernandez-Pol, Sebastian
    Petersen, Bruce
    Murphy, Jo-Ellen
    Oak, Jean S.
    Wang, Erica B. K.
    Rieger, Kerri E.
    Kim, Youn H.
    Khodadoust, Michael S.
    Suarez, Carlos J.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (02) : 193 - 199
  • [29] Allosteric regulation in STAT3 interdomains is mediated by a rigid core: SH2 domain regulation by CCD in D170A variant
    Zhao, Tingting
    Karki, Nischal
    Zoltowski, Brian D.
    Matthews, Devin A.
    PLOS COMPUTATIONAL BIOLOGY, 2022, 18 (12)
  • [30] Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo
    W Huang
    Z Dong
    Y Chen
    F Wang
    C J Wang
    H Peng
    Y He
    G Hangoc
    K Pollok
    G Sandusky
    X-Y Fu
    H E Broxmeyer
    Z-Y Zhang
    J-Y Liu
    J-T Zhang
    Oncogene, 2016, 35 : 783 - 792
12345